イミフィンジ（デュルバルマブ）の世界市場レポート 2025年：疫学、パイプライン分析、市場インサイトと予測

イミフィンジ（デュルバルマブ）の市場規模は、今後数年でほぼ横ばいの成長が見込まれます。2029年にはCAGR11％で41億4,340万米ドルに成長します。予測期間の成長は、併用療法の増加、医薬品研究開発の増加、がん有病率の上昇、免疫療法の受け入れ拡大、規制当局の足跡の増加、ヘルスケア施設への投資の増加に起因しています。予測期間における主な動向としては、個別化医療技術の採用、個別化医療への注力、バイオシミラーの採用、人工知能と機械学習の統合、製薬企業間の提携などが挙げられます。

がんの罹患率の増加がイミフィンジ（デュルバルマブ）市場の成長を牽引すると予想されます。がんは、異常な細胞の無秩序な増殖と拡散を特徴とする疾患群であり、高齢化、喫煙、食生活の乱れ、肥満などががん罹患率の上昇に寄与しているため、ますます罹患率が高まっています。デュルバルマブ（イムフィンジ）は、がん細胞が免疫システムによる検出を回避するのを防ぐPD-L1タンパク質を阻害することにより、がんの治療に使用されます。米国国立がん研究所（NIH）によると、2022年の米国におけるがん生存者数は1,810万人で、2032年には2,250万人に増加すると予想されています。このように、がんの罹患率の上昇が、市場におけるイミンジの需要を牽引しています。

個別化医療の増加は、イミフィンジ（デュルバルマブ）市場の成長を促進すると予想されます。個別化医療は、最も効果的な治療結果を得るために、遺伝的体質、ライフスタイル、環境などの患者個人の特性に基づいて治療を調整するものです。個別化治療の需要は、ゲノム技術、分子生物学、精密診断ツール、副作用を最小限に抑えながら患者の転帰を改善する標的治療の進歩により高まっています。イムフィンジは、PD-L1タンパク質を標的とすることで、がん患者に合わせた免疫療法を可能にし、有効性を向上させ、副作用を軽減することで、個別化医療において重要な役割を果たしています。個別化医療連合によると、FDAは2022年に新薬の34%について個別化医療を承認しており、個別化治療への注目が高まっていることを強調しています。したがって、個別化医療の増加はイムインジ市場の重要な促進要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のイミフィンジ（デュルバルマブ）：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のイミフィンジ（デュルバルマブ）市場：成長率分析
• 世界のイミフィンジ（デュルバルマブ）市場の実績：規模と成長, 2019-2024
• 世界のイミフィンジ（デュルバルマブ）市場の予測：規模と成長, 2024-2029, 2034F
• 世界のイミフィンジ（デュルバルマブ）：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のイミフィンジ（デュルバルマブ）市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 2.4mL注射液
• 10mL注射液
• 世界のイミフィンジ（デュルバルマブ）市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のイミフィンジ（デュルバルマブ）市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所進行尿路上皮がん
• 転移性尿路上皮がん
• その他の用途

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率および有病率

第10章 地域別・国別分析

• 世界のイミフィンジ（デュルバルマブ）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のイミフィンジ（デュルバルマブ）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• イミフィンジ（デュルバルマブ）市場：競合情勢
• イミフィンジ（デュルバルマブ）市場：企業プロファイル
  • AstraZeneca PLC

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、セグメント、戦略

• イミフィンジ（デュルバルマブ）市場2029：新たな機会を提供する国
• イミフィンジ（デュルバルマブ）市場2029：新たな機会を提供するセグメント
• イミフィンジ（デュルバルマブ）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第34章 付録

Imfinzi (durvalumab) is a human monoclonal antibody and immunotherapy drug designed to block programmed death-ligand 1 (PD-L1), a protein that tumors use to evade immune system detection. It is used to treat various cancers, including non-small cell lung cancer, small cell lung cancer, biliary tract cancer, and advanced urothelial carcinoma.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of imfinzi (durvalumab) include 2.4 mL injection and 10 mL injection. The 2.4 mL injection refers to a precise volume of the drug contained in a 2.4 milliliter vial or syringe, often used for accurate dosing during medical treatments. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies for applications such as locally advanced urothelial carcinoma, metastatic urothelial carcinoma, and other indications.

The imfinzi (durvalumab) market research report is one of a series of new reports from The Business Research Company that provides imfinzi (durvalumab) market statistics, including imfinzi (durvalumab) industry global market size, regional shares, competitors with imfinzi (durvalumab) market share, detailed imfinzi (durvalumab) market segments, market trends and opportunities, and any further data you may need to thrive in the imfinzi (durvalumab) industry. This Imfinzi (durvalumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The imfinzi (durvalumab) market size is expected to see parid growth in the next few years. It will grow to $4,143.4 million in 2029 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to growing use of combination therapies, increasing pharmaceutical R&D, rising prevalence of cancer, growing acceptance of immunotherapy, increasing regulatory footprint, and growing investment in healthcare facilities. Major trends in the forecast period include adoption of personalized medicine techniques, a focus on personalized medicine, adoption of biosimilars, integration of artificial intelligence and machine learning, and collaborations between pharmaceuticals.

The growing incidence of cancer is expected to drive the growth of the imfinzi (durvalumab) market. Cancer, a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, is becoming increasingly prevalent due to an aging population, smoking, poor diet, and obesity, all of which contribute to higher cancer rates. Durvalumab (Imfinzi) is used to treat cancer by inhibiting the PD-L1 protein, which prevents cancer cells from evading detection by the immune system. According to the National Cancer Institute (NIH), there were 18.1 million cancer survivors in the U.S. in 2022, with that number expected to rise to 22.5 million by 2032. The rising incidence of cancer is thus driving the demand for imfinzi in the market.

Rising personalized medicine is expected to propel the growth of the imfinzi (durvalumab) market. Personalized medicine tailors treatments based on individual patient characteristics such as genetic makeup, lifestyle, and environment to achieve the most effective outcomes. The demand for personalized treatments is growing due to advancements in genomic technologies, molecular biology, precision diagnostic tools, and targeted therapies that improve patient outcomes while minimizing side effects. Imfinzi, by targeting the PD-L1 protein, plays a critical role in personalized medicine by enabling tailored immunotherapy treatments for cancer patients, improving efficacy and reducing side effects. According to the Personalized Medicine Coalition, the FDA approved personalized medicines for 34% of new drugs in 2022, emphasizing the increasing focus on individualized therapies. Therefore, the rise in personalized medicine is a significant driver for the imfinzi market.

A key trend in the imfinzi (durvalumab) market is the focus on gaining regulatory approvals to expand its use for additional cancer types, enhance clinical indications, and broaden its market reach. Regulatory approvals from authorities like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) allow for the marketing and use of drugs in specific regions. For example, in September 2022, AstraZeneca received FDA approval for durvalumab (Imfinzi) to treat locally advanced or metastatic biliary tract cancer (BTC) in adults. This approval was based on the results of the TOPAZ-1 trial, which showed that durvalumab combined with gemcitabine and cisplatin significantly improved overall survival and progression-free survival in patients with BTC. The success of such trials and regulatory approvals is expected to increase the market reach of Imfinzi, further driving its growth.

Key player operating in the imfinzi (durvalumab) market is AstraZeneca PLC.

North America was the largest region in the imfinzi (durvalumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in imfinzi (durvalumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the imfinzi (durvalumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The imfinzi (durvalumab) market consists of sales of products including Keytruda, Opdivo, Tecentriq, Libtayo, Bavencio and Emerging PD-1/PD-L1 Inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Imfinzi (durvalumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on imfinzi (durvalumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for imfinzi (durvalumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The imfinzi (durvalumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: 2.4mL Injection; 10mL Injection
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By Application: Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Other Applications
• Companies Mentioned: AstraZeneca PLC.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Imfinzi (durvalumab) Market Characteristics

3. Imfinzi (durvalumab) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Imfinzi (durvalumab) Market Trends And Strategies

5. Imfinzi (durvalumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Imfinzi (durvalumab) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Imfinzi (durvalumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Imfinzi (durvalumab) Market Growth Rate Analysis
• 6.4. Global Imfinzi (durvalumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Imfinzi (durvalumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Imfinzi (durvalumab) Total Addressable Market (TAM)

7. Global Imfinzi (durvalumab) Market Pricing Analysis & Forecasts

8. Imfinzi (durvalumab) Market Segmentation

• 8.1. Global Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 2.4mL Injection
• 10mL Injection
• 8.2. Global Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 8.3. Global Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Locally Advanced Urothelial Carcinoma
• Metastatic Urothelial Carcinoma
• Other Applications

9. Global Imfinzi (durvalumab) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Imfinzi (durvalumab) Market Regional And Country Analysis

• 10.1. Global Imfinzi (durvalumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Imfinzi (durvalumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Imfinzi (durvalumab) Market

• 11.1. Asia-Pacific Imfinzi (durvalumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Imfinzi (durvalumab) Market

• 12.1. China Imfinzi (durvalumab) Market Overview
• 12.2. China Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Imfinzi (durvalumab) Market

• 13.1. India Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Imfinzi (durvalumab) Market

• 14.1. Japan Imfinzi (durvalumab) Market Overview
• 14.2. Japan Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Imfinzi (durvalumab) Market

• 15.1. Australia Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Imfinzi (durvalumab) Market

• 16.1. South Korea Imfinzi (durvalumab) Market Overview
• 16.2. South Korea Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Imfinzi (durvalumab) Market

• 17.1. Western Europe Imfinzi (durvalumab) Market Overview
• 17.2. Western Europe Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Imfinzi (durvalumab) Market

• 18.1. UK Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Imfinzi (durvalumab) Market

• 19.1. Germany Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Imfinzi (durvalumab) Market

• 20.1. France Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Imfinzi (durvalumab) Market

• 21.1. Eastern Europe Imfinzi (durvalumab) Market Overview
• 21.2. Eastern Europe Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Imfinzi (durvalumab) Market

• 22.1. North America Imfinzi (durvalumab) Market Overview
• 22.2. North America Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Imfinzi (durvalumab) Market

• 23.1. USA Imfinzi (durvalumab) Market Overview
• 23.2. USA Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Imfinzi (durvalumab) Market

• 24.1. Canada Imfinzi (durvalumab) Market Overview
• 24.2. Canada Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Imfinzi (durvalumab) Market

• 25.1. South America Imfinzi (durvalumab) Market Overview
• 25.2. South America Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Imfinzi (durvalumab) Market

• 26.1. Middle East Imfinzi (durvalumab) Market Overview
• 26.2. Middle East Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Imfinzi (durvalumab) Market

• 27.1. Africa Imfinzi (durvalumab) Market Overview
• 27.2. Africa Imfinzi (durvalumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Imfinzi (durvalumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Imfinzi (durvalumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Imfinzi (durvalumab) Market Competitive Landscape And Company Profiles

• 28.1. Imfinzi (durvalumab) Market Competitive Landscape
• 28.2. Imfinzi (durvalumab) Market Company Profiles
  • 28.2.1. AstraZeneca PLC. Overview, Products and Services, Strategy and Financial Analysis

29. Global Imfinzi (durvalumab) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Imfinzi (durvalumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Imfinzi (durvalumab) Market

32. Recent Developments In The Imfinzi (durvalumab) Market

33. Imfinzi (durvalumab) Market High Potential Countries, Segments and Strategies

• 33.1 Imfinzi (durvalumab) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Imfinzi (durvalumab) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Imfinzi (durvalumab) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer